Yeah that is true too. Will help reduce Glenmarkâs debt. And there are some triggers waiting on Ichnos side too. Management claiming that a couple of molecules will be outlicensed in FY-24 (or raise funding for Ichnos). But take it with a pinch of salt, the management is saying this for a long time now.
Auro also wants to list Eugia, but will only happen once the pharma cycle turns. The past 2 months definitely encouraging for that.
Just found out that generic drug shortages in USA are at multi year high so perhaps better times to come for pharma cos especially export oriented. Need to dive deeper in it, but I dont wanna have much position in this sector as of now. Only a few pharma cos were at good valuations and almost all of them gave a good runup in past 2 months.
| Subscribe To Our Free Newsletter |
